Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer

Withdrawn before enrolling · Phase 2

Conditions studied: Metastatic Colorectal Cancer

In brief

Experimental immunotherapy in chemotherapy-refractory and immunotherapy-refractory metastatic colorectal cancer patients that have progressed, or are intolerant to, Longsurf (TAS-102) +/- Avastin (bevacizumab) or Stivarga (regorafenib) or Fruzaqla (fruquintinib) combining experimental AlloStim with an anti-programmed death ligand 1 (PD-L1) checkpoint inhibitor drug.

Key facts

Study ID

NCT06557278

Run by

Mirror Biologics, Inc.

People needed

0

Starts

2026-11-01

Expected to finish

2028-11-01

Last updated by the study team

2025-10-21

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult male and female subjects aged 18-80 years at screening visit
• Pathologically confirmed diagnosis of MSS/pMMR colorectal adenocarcinoma
• Presenting with metastatic disease:
• Primary tumor can be intact or previously resected
• Previous treatment failure of at least two lines of active systemic chemotherapy:
• Previous chemotherapy must have included a fluoropyrimidine, oxaliplatin (e.g. FOLFOX, CAPOX), and irinotecan-containing (e.g. FOLFIRI) regimens (single regimen of FOLFIRINOX satisfies)
• Administered in adjuvant setting or for treatment of metastatic disease
• If KRAS wild type, must have at least one prior anti-EGFR therapy if left sided primary tumor
• Treatment failure or refusal/not qualified for at least one third-line treatment
• TAS-102 +/- bevacizumab or regorafenib or fruquinib
• Treatment failure can be due to disease progression or toxicity
• Time from last treatment failure to Informed Consent must be no more than 30 days
• ECOG performance score: 0-1
• Adequate hematological function:
• Absolute granulocyte count ≥ 1,200/mm3
• Platelet count ≥ 100,000/mm3
• Hemoglobin ≥ 9.0 g/dL (may be corrected by transfusion)
• Adequate Organ Function:
• Creatinine ≤ 1.5 mg/dL
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 2.5 times ULN *
• Aspartate aminotransferase (AST) or (SGOT) ≤ 2.5 times ULN *
• Alanine aminotransferase (ALT) or (SGPT) ≤ 2.5 times ULN*
• EKG without clinically relevant abnormalities
• Female subjects: Not pregnant or lactating

You may not qualify if…

• High frequency microsatellite instability (MSI-H) or deficient mismatched repair dMMR
• Bowel obstruction or high risk for obstruction if tumors become inflamed
• Moderate or severe ascites requiring medical intervention
• Clinical evidence of brain metastasis or leptomeningeal involvement
• Widespread peritoneal carcinomatous (e.g. CT scan shows innumerable lesions visible and/or abnormal thickening of greater omentum) that increases risk of a major morbidity (e.g. bowel obstruction) in the opinion of the Investigator
• COPD
• Pulmonary lymphangitis or symptomatic pleural effusion (grade ≥ 2) that results in pulmonary dysfunction requiring active treatment; or, oxygen saturation <92% on room air
• Any of the following mood disorders: active major depressive episode, recent history of suicidal attempt or ideation
• Prior allogeneic bone marrow/stem cell or solid organ transplant
• Chronic use (> 2 weeks) of greater than physiologic doses of a corticosteroid agent (dose equivalent to > 5 mg/day of prednisone) planned or anticipated during the study before the end of the Safety Evaluation Period (28 days after the last dose of IP)
• Topical corticosteroids are permitted
• Prior diagnosis of an active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, autoimmune thyroid disease, uveitis)
• Well controlled Type I diabetes allowed (HbA1c < 8.5%)
• Prior experimental immunotherapy
• History of blood transfusion reactions
• Progressive viral or bacterial infection
• o All infections must be resolved and the subject must remain afebrile for seven days without antibiotics prior to being placed on study
• Cardiac disease of symptomatic nature
• History of HIV positivity or AIDS
• History of severe hypersensitivity to monoclonal antibody drugs
• Psychiatric or addictive disorders or other condition that, in the opinion of the Investigator, would preclude study participation.
• Subjects that lack ability to provide consent for themselves
• Any prior cancer diagnosis (other than cured basal cell carcinoma, head and neck carcinoma in-situ, superficial Ta, Tis, T1 bladder cancer, or papillary carcinoma of thyroid) or concurrent cancer histologically different than colorectal adenocarcinoma

Where it is running

• Mt. Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States
• Hirschfield Oncology Center — Brooklyn, New York, United States
• New York Cancer and Blood Specialists — Shirley, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.